



Resource impact statement

Resource impact

Published: 2 February 2022

www.nice.org.uk

No significant resource impact is anticipated

NICE has recommended pembrolizumab as an option for the adjuvant treatment of completely resected stage 3 melanoma with lymph node involvement in adults. It is recommended only if the company provides pembrolizumab according to the commercial arrangement (see section 2 of the guidance).

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).

This is because the technology is a further treatment option and the overall treatment cost will be similar.

Pembrolizumab and the other treatment options (nivolumab, and dabrafenib with trametinib) have discounts that are commercial in confidence. For enquiries about the patient access schemes contact the relevant companies.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.